Lady Mayor’s Show: Dame Susan Langley champions innovation in the Square Mile November 8, 2025 On Saturday, for the first time in nearly 700 years, the City of London’s Lord Mayor’s Show has been renamed the Lady Mayor’s Show. This follows the election of Dame Susan Langley DBE as the 697th Lord Mayor of London. While she is the third woman to hold the post, Dame Susan is the first [...]
Tech stocks fall again as AI bubble fears mount November 8, 2025 Tech stocks fell again on Friday, extending a difficult week for the sector as investors fretted over soaring valuations and a possible AI bubble. Leading names including Nvidia, Palantir, Meta, AMD, and Tesla all suffered losses, erasing gains from earlier in the year and intensifying concerns about whether AI-driven growth can justify current market prices. [...]
Can the government force the Abramovich Chelsea money to go to Ukraine? November 8, 2025 This week former Chelsea owner Roman Abramovich hit out at the UK government over their handling of the proceeds from the sale of the Blues to a Todd Boehly-fronted consortium, describing the process as “paralysing”. Around £2.3bn is sitting frozen in a bank account with the two parties at odds over whether Ukraine, or “all” [...]
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage” November 8, 2025 OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, [...]
Business Leaders and Experts Urge for Smarter Planning in London November 7, 2025 London, 7 November 2025 – Business leaders, policymakers, and industry experts gathered last month at the Emmanuel Centre, Westminster “London – Opportunities and Obstacles for Growth,” organised by the Central London Alliance CIC. The event explored the challenges and opportunities shaping London’s economic future featuring six panel discussions delving into the key features of the [...]
Pensions, motorists and workers: The tax targets Rachel Reeves is eyeing up November 7, 2025 If there is one thing that is clear three weeks out from the Autumn Budget, it is that Chancellor Rachel Reeves will hike taxes. The Office for Budget Responsibility (OBR), which scores the economic impacts of the government’s policies and publishes forecasts on public finances, has been questioned for being over optimistic on measures such [...]
Sky in talks to buy ITV’s broadcasting arm for £1.6bn November 7, 2025 ITV has confirmed it is in early talks with Sky over the possible sale of its media and entertainment division, in a move that could reshape the UK television industry. In a statement to the market on Friday, ITV announced that it was in “preliminary discussions” regarding a potential sale of its broadcasting and streaming [...]
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights November 6, 2025 Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025 Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025 Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
From insights to impact, Leinster Rugby leverages data strategy to level up fan experience November 6, 2025 BearingPoint supports the club in creating a roadmap for personalized experiences and future-ready innovation.
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights November 6, 2025 SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028